Xlife Sciences AG is a Switzerland-based publicly listed incubator and accelerator in the life sciences sector. It specializes in the value development and commercialization of promising early-stage research projects from universities and research institutions, bridging the gap between research and development and healthcare markets. The company focuses on four key areas: technology platforms, biotechnologies and therapies, medical technology including health technology, and artificial intelligence in digital health. Notable initiatives include identifying innovative biomarkers for kidney diseases, developing antibody-drug conjugates via click chemistry and microfluidic screening, and offering Neuromex, a screening tool for early detection of neurological diseases like Alzheimer's. Xlife Sciences AG also manufactures chemical and active pharmaceutical ingredients for human and veterinary medicines and provides clinical research organization services. Founded in 2019 and headquartered in Zurich, it supports researchers and entrepreneurs while emphasizing sustainability, such as minimizing animal testing and low-energy production processes. With around 17 employees, it plays a vital role in advancing solutions for unmet medical needs.